Skip to main content
Premium Trial:

Request an Annual Quote

MIT Drug-Discovery Spinout ReviveMed Raises $1.5M

NEW YORK (GenomeWeb) – ReviveMed said today that it has closed a $1.5 million seed funding round to advance its artificial intelligence-driven metabolomics platform for drug discovery and development.

Rivas Capital led the round, which also included participation from several institutional investors including TechU, Team Builder Ventures, and WorldQuant Ventures.

A group of researchers led by Leila Pirhaji, founder and CEO of ReviveMed and former postdoc at the Massachusetts Institute of Technology, published proof of concept for the company's technology in August 2016 in Nature Medicine, using Huntington's disease as a model.

"Metabolomics data provide a critical link between the activity of genes and proteins, and phenotypic behavior in normal and disease states," Pirhaji said in a statement. "However, despite its potential, metabolomics has been greatly underutilized due to the difficulty of identifying a large number of metabolites in each patient. Our platform for the first time enables the rapid, high-throughput, and cost-effective application of metabolic data to discover new disease mechanisms for drug discovery and, simultaneously metabolomic biomarkers to identify which patients stand to benefit by targeting the disease mechanism."

ReviveMed's initial internal discovery program is in metabolic diseases and focused specifically on non-alcohol fatty liver disease.

In connection with the financing, Rivas Capital Founder Carlos Gonzalez will join the ReviveMed board of directors.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.